Evaluation Only. Created with Aspose.PDF. Copyright 2002-2021 Aspose Pty Ltd.
Regioselective One-Pot Synthesis of
9-Alkyl-6-chloropyrido[3,2-e][1,2,4]triazolo-
[4,3-a]pyrazines. Reactivity of Aliphatic
and Aromatic Hydrazides
Asier Unciti-Broceta,† Maria J. Pineda-de-las-Infantas,†
Juan J. D´ıaz-Mocho´n,†,§ Romeo Romagnoli,‡
Pier G. Baraldi,‡ Miguel A. Gallo,† and
Antonio Espinosa*,†
FIGURE 1. The structure of 4-(diethylamino)[1,2,4]triazolo-
[4,3-a]quinoxaline (CP-41,475), a tricycle nonxanthine adeno-
sine antagonist.
dichloroquinoxaline.7,8 Following the reaction with hy-
drazine, triethyl orthoalkanoates are used to accomplish
the ring closure (Scheme 1). This methodology suffers
from drawbacks such as moderate yields, side product
formation, and the two-step synthesis of the fused triazolo
ring. Other strategies have also been reported but
without major improvements.9,10
Departamento de Quı´mica Farmace´utica y Orga´nica,
Facultad de Farmacia, Campus Cartuja s/n,
18071 Granada, Spain, and Dipartimento di Scienze
Farmaceutiche, Via Fossato di Mortara 17/19,
I/44100, Ferrara, Italy
Herein, we report the synthesis of 9-alkyl-6-chloro-
pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazines which were
obtained from 2,3-dichloropyrido[2,3-b]pyrazine 3 in a
single step. A first approach to obtain these fused
heterocycles starting from 3 as depicted in Scheme 1 also
resulted in low yield reactions and side product forma-
tion. We devised a new synthetic pathway to overcome
some of the previous drawbacks and which provided a
more straightforward and flexible synthesis of new
tricycle nonxanthine adenosine antagonists. The cyclo-
condensation involved nucleophilic displacement followed
by cyclization using several aliphatic and aromatic hy-
drazides. The key step was the regioselective nucleophilic
aromatic substitution that gave rise to unique isomers
before ring closure.
The dichloro derivative 3 was prepared from com-
mercially available 2,3-diaminopyridine 1 in very high
yields, following the procedure outlined in Scheme 2.
Synthesis of the 5-azaquinoxaline ring were achieved by
using oxalic acid in 4 N HCl aqueous solution.11 Halo-
genation of 2 by treatment with thionyl chloride and
DMF in catalytic amounts provided 3.12
Following reaction between 3 and aliphatic hydrazides
unique tricyclic isomers were isolated in good yields.13
The reaction that leads to tricycles 4a-e proceeded
through the nucleophilic attack of the corresponding
aliphatic hydrazide to the more electrophilic position of
the 2,3-dichloropyrido[2,3-b]pyrazine system (Scheme 3).
Therefore, the position of the nitrogen contained in the
pyrido ring dictates the regiochemistry of the reaction.
The corresponding hydrazones14 then afford compounds
Received December 7, 2004
The one-pot synthesis of new 9-alkyl-6-chloropyrido[3,2-e]-
[1,2,4]triazolo[4,3-a]pyrazines has been achieved. Hydrazides
regioselectively reacted as nucleophiles with the 3-chloro
substituent of 2,3-dichloropyrido[2,3-b]pyrazine. An intra-
molecular cyclization afforded the tricycle nonxanthine
adenosine receptor antagonists.
The tricyclic nonxanthine adenosine antagonists are
nitrogen-containing heterocycles based on the adenosine
moiety.1-3 During an empirical screening effort, it was
discovered that 4-(diethylamino)[1,2,4]triazolo[4,3-a]qui-
noxaline4 (CP-41,475, Figure 1) was effective in reducing
immobility in rats following a single dose.5 These results
suggested that compounds with structures related to this
family might therefore be rapid-onset antidepressants.
Furthermore, biochemical studies early on indicated that
these compounds displayed adenosine receptor affini-
ties.1,5 Currently, this class of compounds is being inves-
tigated and the results have been reported.6
The traditional synthetic strategy for these fused
heterocycles involves a two-step approach from 2,3-
(7) Shiho, D.; Tagami, S. J. Am. Chem. Soc. 1960, 82, 4044-4054.
(8) Sarges, R. U.S. Patent 4495187, 1985.
* To whom the correspondence should be addressed. Fax: +34-958-
243845. Phone: +34-958-243850.
(9) Bradan, M. M.; Abouzid, K. A. M.; Hussein, M. H. M. Arch.
Pharm. Res. 2003, 26, 107-113.
† Universidad de Granada.
(10) Rashed, N.; El Massry, A. M.; El Ashry, E. S. H.; Amer, A.;
Zimmer, H. J. Heterocycl. Chem. 1990, 27, 691-694.
§ Current address: School of Chemistry, Highfield Campus,
Southampton, SO17 1BJ, UK.
(11) Ohmori, J.; Shimizu-Sasamata, M.; Okada, M.; Sakamoto, S.
J. Med. Chem. 1997, 40, 2053-2063.
‡ Universita` di Ferrara.
(1) Trivedi, B. K.; Bruns, R. F. J. Med. Chem. 1988, 31, 1011-1014.
(2) Mu¨ller, C. E.; Stein B. Curr. Pharm. Des. 1996, 2, 501-530.
(3) Jacobson, K. A.; Suzuki, F. Drug Dev. Res. 1990, 39, 289-300.
(4) This compound was initially prepared by Dr. S. B. Kadin at Pfizer
Central Research for antiallergy testing.
(12) Ohmori, J.; Kubota, H.; Shimizu-Sasamata M.; Okada M.;
Sakamoto, S. J. Med. Chem. 1996, 39, 1331-1338.
(13) To a solution of 2,3-dichloropirido[2,3-b]pirazine 3 (0.2 g, 1
mmol) and suitable hydrazide (1 mmol) in THF or acetonitrile (10 mL)
was added dropwise a solution of concentrated H2SO4 (54 µL, 1 mmol)
in THF or acetonitrile (5 mL) and the mixture was refluxed for 20 h.
(14) These compounds were observed by TLC. The bigger the
substituent R, the higher the stability of the corresponding hydrazones.
(5) Sarges, R.; Howard, H. R.; Browne, R. G.; Lebel L. A.; Seymour,
P. A.; Koe, B. K. J. Med. Chem. 1990, 33, 2240-2254.
(6) Matuszczak, B.; Mueller, C. E. PCT Int. Appl. WO 03/053973.
10.1021/jo0478398 CCC: $30.25 © 2005 American Chemical Society
Published on Web 03/05/2005
2878
J. Org. Chem. 2005, 70, 2878-2880